Quick Answer
Aligos Therapeutics, Inc. reported Earnings Per Share Diluted of $2.45 (loss) per share for the year ending 2025.
- Aligos Therapeutics, Inc. showed an increase of +88.3% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Aligos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2022 to 2025), Aligos Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 8.9%.
- Historical annual values: Fiscal year 2025: $2.45 (loss) per share | Fiscal year 2024: $20.94 (loss) per share | Fiscal year 2023: $34.20 (loss) per share | Fiscal year 2022: $2.25 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: